Publications by authors named "D W Pook"

Claim this Profile
T
The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study.
Michael Michael, Guy C Toner, Vinod Ganju, Emma Link, Mick Thompson, David W Pook

Br J Clin Pharmacol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial.
Martin H Voss, Howard Gurney, Vagif Atduev, Cristina Suarez, Miguel A Climent, David Pook

Eur Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study.
J N Graff, M Burotto, P C Fong, D W Pook, B Zurawski

Ann Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).
Alexander M Menzies, Pamela Salman, Osvaldo Arén Frontera, David Pook, Christopher M Hocking

Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravesical gemcitabine and docetaxel vs. re-induction Bacillus Calmette Guerin as first-line salvage therapy for non-muscle invasive bladder cancer.
Kylie Yen-Yi Lim, Tran Ngoc An Huynh, Gavin Wei, Jincy Kuriakose, Obaidullah Fazli, David Pook

BJUI Compass· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis